Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

But it's the Pfizer case that seems to me to be a more important harbinger of the challenges companies may face as they try to encourage diversity and inclusion in the workplace.

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), its partner for the Comirnaty COVID-19 vaccine, made legal submissions to London's Court of Appeal on Thursday seeking to overturn a prior court ruling ...

Pfizer and the direct purchasers entered into the settlement agreement Nov. 22. The agreement still needs official court approval. More articles on legal & regulatory issues: ...

Oct 3 (Reuters) - An advocacy group that opposes diversity initiatives in medicine urged a federal appeals court on Tuesday to revive its lawsuit claiming a fellowship program offered by Pfizer ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a ...

The 2nd U.S. Circuit Court of Appeals ruled in favor of Pfizer (PFE), in a lawsuit by Do No Harm challenging the company's diversity fellowship program. Read more here.

Pfizer said its Wyeth unit has agreed to pay a $784.6 million settlement for cases related to the calculation of Medicaid rebates for a gastric drug sold between 2001 and 2006, according to Reuters.

Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases Aug. 30, 2023 4:04 PM ET Moderna, Inc. (MRNA) Stock , PFE Stock ABUS , ALNY , BNTX , CVAC , MRNA , PFE 46 Comments 16 Likes ...

In light of the rapid spread of the delta variant and full FDA approval of the Pfizer COVID-19 vaccine, many employers are either now implementing or considering a vaccine mandate.

The court held that DNH lacked legal standing and dismissed the challenge to Pfizer’s diversity program. The Second Circuit’s decision creates a potential roadblock for challenges levied by ...